Analysts forecast that Arcturus Therapeutics Ltd (NASDAQ:ARCT) will post earnings per share (EPS) of ($0.60) for the current quarter, Zacks reports. Two analysts have made estimates for Arcturus Therapeutics’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.56). Arcturus Therapeutics posted earnings per share of ($0.50) during the same quarter last year, which would indicate a negative year over year growth rate of 20%. The company is scheduled to announce its next quarterly earnings report on Monday, October 7th.
On average, analysts expect that Arcturus Therapeutics will report full-year earnings of ($2.41) per share for the current financial year, with EPS estimates ranging from ($2.54) to ($2.31). For the next financial year, analysts forecast that the business will report earnings of ($2.09) per share, with EPS estimates ranging from ($2.41) to ($1.69). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Arcturus Therapeutics.
Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.15). Arcturus Therapeutics had a negative net margin of 124.59% and a negative return on equity of 132.46%. The business had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $3.47 million.
ARCT stock opened at $6.45 on Monday. Arcturus Therapeutics has a 12 month low of $4.11 and a 12 month high of $10.00. The firm has a market capitalization of $69.41 million, a P/E ratio of -2.99 and a beta of 2.19. The company has a quick ratio of 2.51, a current ratio of 2.51 and a debt-to-equity ratio of 2.43.
A number of institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC raised its position in Arcturus Therapeutics by 13.7% during the 1st quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock worth $6,332,000 after buying an additional 111,968 shares during the last quarter. Nikko Asset Management Americas Inc. purchased a new position in Arcturus Therapeutics during the 1st quarter worth $438,000. Finally, Creative Planning purchased a new position in Arcturus Therapeutics during the 1st quarter worth $416,000. Institutional investors own 13.58% of the company’s stock.
About Arcturus Therapeutics
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.